Drug · CHEMBL973

TERIFLUNOMIDE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. TERIFLUNOMIDE. Drugs and targets, record CHEMBL973. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL973

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: TERIFLUNOMIDE; ChEMBL
ChEMBL ID: CHEMBL973; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Aubagio, Teriflunomide accord, Teriflunomide mylan; ChEMBL
Other names: A77 1726, HMR-1726, HMR1726, Leflunomide related compound b, Leflunomide related compound b rs, Teriflunomida; ChEMBL
DrugBank: DB08880; DrugBank
InChIKey: UTNUDOFZCWSZMS-YFHOEESVSA-N; ChEMBL
Open Targets' highest stage: Approval, for 3 of its 10 diseases, from DailyMed, EMA Human Drugs and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
DHODH	Dihydroorotate dehydrogenase (quinone), mitochondrial	Dihydroorotate dehydrogenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/1723

Source ChEMBL

Diseases10

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
multiple sclerosis symptom measurement	Approval	DailyMed, EMA Human Drugs and TTD	42	39	https://conductscience.org/library/drugs?q=EFO_0803536
autoimmune thrombocytopenic purpura	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0008558
relapsing-remitting multiple sclerosis	Approval	EMA Human Drugs	3	1	https://conductscience.org/library/drugs?q=MONDO_0005314
rheumatoid arthritis	Phase 3	TTD	2	1	https://conductscience.org/library/drugs?q=MONDO_0008383
celiac disease	Phase 1/2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005130
hepatotoxicity	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=EFO_0011052
secondary progressive multiple sclerosis	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0000450
tropical spastic paraparesis	Phase 1/2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0008039
familial hyperlipidemia	Approval	TTD	1	0	https://conductscience.org/library/drugs?q=MONDO_0001336
hepatitis B virus infection	Phase 1	TTD	1	0	https://conductscience.org/library/drugs?q=MONDO_0005344

Source Open Targets

Trials57

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00751881	An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis	Phase 3	1,169	2013-06-26	teriflunomide	Its name	ClinicalTrials.gov
NCT04338061	Study of Evobrutinib in Participants With RMS (evolutionRMS 2)	Phase 3	1,166	2025-01-14	teriflunomide	Its name	ClinicalTrials.gov
NCT02425644	Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis	Phase 3	1,133	2021-06-11	teriflunomide	Its name	ClinicalTrials.gov
NCT04338022	Study of Evobrutinib in Participants With RMS (evolutionRMS 1)	Phase 3	1,124	2025-06-12	teriflunomide	Its name	ClinicalTrials.gov
NCT00134563	Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis	Phase 3	1,088	2012-11-06	teriflunomide	Its name	ClinicalTrials.gov
NCT01895335	Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients	Phase 4	1,001	2016-12-06	teriflunomide	Its name	ClinicalTrials.gov
NCT04410978	Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)	Phase 3	974	2025-06-18	teriflunomide	Its name	ClinicalTrials.gov
NCT02792231	Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.	Phase 3	955	2020-10-19	teriflunomide	Its name	ClinicalTrials.gov
NCT02792218	Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis	Phase 3	930	2020-10-19	teriflunomide	Its name	ClinicalTrials.gov
NCT04410991	Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)	Phase 3	899	2025-06-18	teriflunomide	Its name	ClinicalTrials.gov

1 to 10 of 57

See all 57 trials

Comparisons in its trials20

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Teriflunomide vs Evobrutinib: deaths from any cause	0 of 583	0 of 581	1,164	NCT04338061	Trial comparisons
Teriflunomide vs Evobrutinib: serious adverse events	37 of 583	51 of 581	1,164	NCT04338061	Trial comparisons
Ponesimod 20 mg vs Teriflunomide 14 mg: deaths from any cause	0 of 565	2 of 566	1,131	NCT02425644	Trial comparisons
Ponesimod 20 mg vs Teriflunomide 14 mg: serious adverse events	49 of 565	46 of 566	1,131	NCT02425644	Trial comparisons
Teriflunomide vs Evobrutinib: deaths from any cause	1 of 563	1 of 559	1,122	NCT04338022	Trial comparisons
Teriflunomide vs Evobrutinib: serious adverse events	33 of 563	45 of 559	1,122	NCT04338022	Trial comparisons
Teriflunomide 14 mg vs Tolebrutinib 60 mg: deaths from any cause	0 of 488	0 of 486	974	NCT04410978	Trial comparisons
Teriflunomide 14 mg vs Tolebrutinib 60 mg: serious adverse events	40 of 488	42 of 486	974	NCT04410978	Trial comparisons
OMB 20mg vs TER 14mg: deaths from any cause	0 of 481	1 of 474	955	NCT02792231	Trial comparisons
OMB 20mg vs TER 14mg: serious adverse events	42 of 481	37 of 474	955	NCT02792231	Trial comparisons

1 to 10 of 20

See all 20 comparisons in its trials

Papers from its trials48

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39307151	RESULT	2	PubMed
34950502	RESULT	1	PubMed
30870983	RESULT	1	PubMed
30729028	RESULT	1	PubMed
24461574	RESULT	1	PubMed
24126064	RESULT	1	PubMed
23851964	RESULT	1	PubMed
22622860	RESULT	2	PubMed
21991951	RESULT	1	PubMed
16567708	RESULT	1	PubMed

1 to 10 of 48

See all 48 papers from its trials

Tests in its trials9

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	Source
Symbol Coding	12	ConductCognition
Verbal Learning	2	ConductCognition
Category Fluency	1	ConductCognition
Paced Visual Serial Addition Test	1	ConductCognition
Selective Reminding Task	1	ConductCognition
Task Switching Test	1	ConductCognition
Trail Making Test A	1	ConductCognition
Trail Making Test B	1	ConductCognition
Verbal Fluency	1	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL973

GET https://conductscience.org/api/drugs/v1/CHEMBL973/trials?page=2

API reference For AI assistants